Back to Atlas
CTransientStandard research/education caution
CMP-0416
Investigational / research
Peptide YY (3-36)
Satiety / Metabolic
May reduce appetite and food intake in infusion/research settings
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Gut hormone peptide analog
- Primary mechanism
- Selective Y2 receptor agonism after DPP-4 processing
- Primary market use
- Obesity/satiety research
Pharmacology
- Molecular weight (Da)
- 4,049.5
- Oral bioavailability
- N/A (peptide; not oral)
- Half-life
- ~15 min IV
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Human/Clinical investigational
- Clinical status
- Investigational / research
- Value-for-money score
- 3 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Native PYY3-36 has strong satiety biology but very short half-life